Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell Ho

Showing results (71-80 of 143) with videos related to

Pageof 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patientsMitchell Ho, Raffit Hassan, Jingli Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 21, 2005
Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapySatoshi Nagata, Tomoko Ise, Masanori Onda, et al.
Molecular Cancer Therapeutics|May 7, 2009
A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicityYang Feng, Xiaodong Xiao, Zhongyu Zhu, et al.
Scientific Reports|May 22, 2015
New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesotheliomaYi-Fan Zhang, Yen Phung, Wei Gao, et al.
The Analyst|October 23, 2010
High-throughput 3D spheroid culture and drug testing using a 384 hanging drop arrayYi-Chung Tung, Amy Y Hsiao, Steven G Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesotheliomaMasanori Onda, Satoshi Nagata, Mitchell Ho, et al.
Hepatology (Baltimore, Md.)|February 5, 2014
Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapyWei Gao, Heungnam Kim, Mingqian Feng, et al.
Hepatology Communications|January 16, 2026
Preclinical development of mesothelin-targeting CAR T cells for the treatment of cholangiocarcinomaJinchutha Duangdara, Shaoli Lin, Jessica Hong, et al.
Biorxiv : the Preprint Server for Biology|June 26, 2025
Temporal mapping of the anti-tumor effects of nanobody-based MSLN.CAR-T cell therapy in metastatic solid tumorsChaido Stathopoulou, Mingming Zhao, Qun Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
Mesothelin expression in human lung cancerMitchell Ho, Tapan K Bera, Mark C Willingham, et al.
Pageof 15

Showing results (71-80 of 143) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patientsMitchell Ho, Raffit Hassan, Jingli Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 21, 2005
Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapySatoshi Nagata, Tomoko Ise, Masanori Onda, et al.
Molecular Cancer Therapeutics|May 7, 2009
A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicityYang Feng, Xiaodong Xiao, Zhongyu Zhu, et al.
Scientific Reports|May 22, 2015
New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesotheliomaYi-Fan Zhang, Yen Phung, Wei Gao, et al.
The Analyst|October 23, 2010
High-throughput 3D spheroid culture and drug testing using a 384 hanging drop arrayYi-Chung Tung, Amy Y Hsiao, Steven G Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesotheliomaMasanori Onda, Satoshi Nagata, Mitchell Ho, et al.
Hepatology (Baltimore, Md.)|February 5, 2014
Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapyWei Gao, Heungnam Kim, Mingqian Feng, et al.
Hepatology Communications|January 16, 2026
Preclinical development of mesothelin-targeting CAR T cells for the treatment of cholangiocarcinomaJinchutha Duangdara, Shaoli Lin, Jessica Hong, et al.
Biorxiv : the Preprint Server for Biology|June 26, 2025
Temporal mapping of the anti-tumor effects of nanobody-based MSLN.CAR-T cell therapy in metastatic solid tumorsChaido Stathopoulou, Mingming Zhao, Qun Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
Mesothelin expression in human lung cancerMitchell Ho, Tapan K Bera, Mark C Willingham, et al.
Pageof 15